Basilea-Pfizer’s Cresemba Heads For Indian Debut
Basilea’s Cresemba appears on course to a debut in India and partner Pfizer expects the novel antifungal to bolster its existing portfolio in the segment. Pricing of the product will be keenly watched.
You may also be interested in...
Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.
Swiss company Basilea has attracted Pfizer as a European partner for its antifungal Cresimba and plans to strengthen its development pipeline with licensed-in products and further collaborations.
Ex-WHO executive and co-chair of the Asia Pacific Immunization Coalition, Tikki Pangestu, outlined at a recent briefing why he believes herd immunity for COVID-19 will not be achievable against the backdrop of the global spread of the highly contagious Delta variant. Facets of vaccine hesitancy and the complexity of vaccine manufacturing were among the other issues discussed by experts.